The estimated Net Worth of Jacob A Frenkel is at least $1.86 Thousand dollars as of 8 May 2019. Jacob Frenkel owns over 1,959 units of Brainstorm Cell Therapeutics stock worth over $1,858 and over the last 15 years he sold BCLI stock worth over $0. In addition, he makes $0 as Chairman of the Board at Brainstorm Cell Therapeutics.
Jacob has made over 2 trades of the Brainstorm Cell Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 1,959 units of BCLI stock worth $549 on 8 May 2019.
The largest trade he's ever made was exercising 2,141 units of Brainstorm Cell Therapeutics stock on 8 May 2018 worth over $599. On average, Jacob trades about 75 units every 7 days since 2009. As of 8 May 2019 he still owns at least 6,636 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of Jacob Frenkel stock trades at the bottom of the page.
Jacob Frenkel is the Chairman of the Board at Brainstorm Cell Therapeutics.
Jacob's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS, 28TH FLOOR, NEW YORK, NY, 10019.
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger, and International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: